Overview
Leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair and replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The emergent platinum drugs of the future - orally active agents, the sterically hindered ZD0473, and the polynuclear charged platinum BBR3464 - are also fully considered. Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs.
Full Product Details
Author: Lloyd R. Kelland ,
Nicholas P. Farrell
Publisher: Humana Press Inc.
Imprint: Humana Press Inc.
Edition: 2000 ed.
Dimensions:
Width: 15.50cm
, Height: 2.00cm
, Length: 23.50cm
Weight: 0.675kg
ISBN: 9780896035997
ISBN 10: 0896035999
Pages: 341
Publication Date: 24 March 2000
Audience:
College/higher education
,
Professional and scholarly
,
Undergraduate
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: In Print
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.
Reviews
This volume of the Cancer Drug Discovery and Development series provides comprehensive coverage of some of the basic science associated with cisplatin, its interaction with DNA and how recognitions and processing of platinum-DNA adducts may be associated with tumour response or resistance. ...Bringing together the most recent research in the area of platinum drugs...The editors of this book have produced a collection of articles which will be of interest to those who need an introduction to the field of platinum drugs. For anyone already familiar with the field, the chapters on the newer analogues and on some of the more recent basic molecular pharmacology issues will provide a useful update. -The Lancet The great attention is also paid to all toxicological aspects of platinum drugs from both clinical and regulatory perspective.... The Platinum-based Drugs in Cancer Therapy appears to be a comprehensive book useful for scientist, medical oncologist and pharmacist seeking answer on specific questions concerning preclinical and clinical data of platinum drugs. -Neoplasma The strength of the text lies in the diversity of topics that are covered in such a succinct fashion. Clinicians will benefit from the earlier focus on basic chemistry and biochemistry, while the bench scientist will better appreciate the practicalities of using these compounds from the lucid experiences of the clinical case studies. -Journal of Medicinal Chemistry This is a useful reference book for scientists and practitioners who have a focus or interest in the chemistry and biochemistry of the platinum compounds. Oncologists will find it helpful for its summary of applications of cisplatin and carboplatin, especially in combination with paclitaxel. --Oncology Journal, November, 2000 ...the book should find its place in the library of many laboratories involved mainly in preclinical oncological research. -Annals of Oncology This new book by Kelland and Farrell is a well-constructed and authoritative account of current knowledge concerning the pharmacology and clinical application of platinum anticancer drugs. It is well illustrated with clear diagrams and appropriate data. ...Not only do platinum agents remain a key component of current cancer therapy for the majority of common solid tumours but recent advances have demonstrated the scope for expansion of the clinical spectrum of activity, the ability to overcome resistance, and the potential introduction of oral delivery. - Clinical Oncology
This volume of the Cancer Drug Discovery and Development series provides comprehensive coverage of some of the basic science associated with cisplatin, its interaction with DNA and how recognitions and processing of platinum-DNA adducts may be associated with tumour response or resistance. Bringing together the most recent research in the area of platinum drugs The editors of this book have produced a collection of articles which will be of interest to those who need an introduction to the field of platinum drugs. For anyone already familiar with the field, the chapters on the newer analogues and on some of the more recent basic molecular pharmacology issues will provide a useful update. - The Lancet The great attention is also paid to all toxicological aspects of platinum drugs from both clinical and regulatory perspective. The Platinum-based Drugs in Cancer Therapy appears to be a comprehensive book useful for scientist, medical oncologist and pharmacist seeking answer on specific questions concerning preclinical and clinical data of platinum drugs. - Neoplasma The strength of the text lies in the diversity of topics that are covered in such a succinct fashion. Clinicians will benefit from the earlier focus on basic chemistry and biochemistry, while the bench scientist will better appreciate the practicalities of using these compounds from the lucid experiences of the clinical case studies. - Journal of Medicinal Chemistry This is a useful reference book for scientists and practitioners who have a focus or interest in the chemistry and biochemistry of the platinum compounds. Oncologists will find it helpful for its summary of applications of cisplatin and carboplatin, especially in combination with paclitaxel. Oncology Journal, November, 2000 the book should find its place in the library of many laboratories involved mainly in preclinical oncological research. - Annals of Oncology This new book by Kelland and Farrell is a well-constructed and authoritative account of current knowledge concerning the pharmacology and clinical application of platinum anticancer drugs. It is well illustrated with clear diagrams and appropriate data. Not only do platinum agents remain a key component of current cancer therapy for the majority of common solid tumours but recent advances have demonstrated the scope for expansion of the clinical spectrum of activity, the ability to overcome resistance, and the potential introduction of oral delivery. - Clinical Oncology
